Anti-inflammatory research
A three-amino-acid fragment of α-MSH studied for its ability to switch off inflammatory signaling at the source.
KPV is the tail end of α-MSH, a hormone your body makes that has, among other jobs, a potent anti-inflammatory role. Researchers found that this three-amino-acid fragment retains much of the anti-inflammatory activity while shedding the pigmentation and other systemic effects of the full hormone. It is small — small enough to be studied topically, orally, and by injection, which is unusual and useful.
Most anti-inflammatories work downstream — they block one of the products of inflammation. KPV works further up, at the switch. It interferes with NF-κB, the transcription factor that turns on inflammatory gene programs in the first place. Turn down the switch and the whole downstream cascade quiets rather than one branch of it.
KPV binds melanocortin receptors MC-1R and MC-3R with lower affinity than α-MSH, activating adenylyl cyclase/cAMP/PKA/CREB signaling toward anti-inflammatory gene transcription. Critically, it inhibits NF-κB nuclear translocation, reducing TNF-α, IL-1β, and IL-6 while increasing IL-10 and TGF-β. It also inhibits mast cell degranulation and increases epithelial tight junction proteins including claudin-1 and occludin — the basis of interest in gut barrier integrity. At roughly 371 daltons it is viable topically, orally, subcutaneously, and intranasally.
Anti-inflammatory effects are relatively quick by peptide standards — a matter of hours rather than weeks — but KPV does not build tissue. Its contribution is making conditions favorable, which is why it more often appears alongside repair compounds than alone.
Every page on this site includes this section. If a source only tells you what something does, you are reading marketing.
Reported tolerability is favorable across the available studies, including topical human use. Not FDA- or EMA-approved. Because it modulates immune signaling, anyone with an autoimmune condition or on immunomodulating therapy should involve their prescriber before considering it. Not appropriate during pregnancy or breastfeeding.
Short peptides are easier to synthesize but no easier to verify by eye — third-party purity testing with a batch-matched certificate of analysis remains the standard.
No. They are frequently used together but do different jobs — KPV suppresses inflammatory signaling, BPC-157 drives tissue repair and blood supply.
That single addition is the difference between the two. KLOW is the choice when inflammation is the limiting factor; GLOW is for straightforward repair and cosmetic improvement.
Its small size makes topical use feasible, and most of the limited human data is topical.
General education only goes so far. If you want help deciding whether this is relevant to your goals, history, and current labs, schedule a consultation with the Bearing team.
Request a Consultation